- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case T-493/12: Judgment of the General Court of 24 September 2014 — Sanofi v OHIM — GP Pharm (GEPRAL) (Community trade mark — Opposition proceedings — International registration designating the European Community — Word mark GEPRAL — Earlier international word mark DELPRAL — Relative ground for refusal — Likelihood of confusion — Article 8(1)(b) of Regulation (EC) No 207/2009)
ECLI:EU:UNKNOWN:62012TA0493
62012TA0493
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
Official Journal of the European Union
C 388/12
(Case T-493/12) (<span class="super">1</span>)
((Community trade mark - Opposition proceedings - International registration designating the European Community - Word mark GEPRAL - Earlier international word mark DELPRAL - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EC) No 207/2009))
2014/C 388/14
Language of the case: English
Parties
Applicant: Sanofi SA (Paris, France) (represented by: C. Hertz-Eichenrode, lawyer)
Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs) (represented by: P. Geroulakos, acting as Agent)
Other party to the proceedings before the Board of Appeal of OHIM: GP Pharm SA (Sant Quinti de Mediona, Spain)
Re:
Action brought against the decision of the Second Board of Appeal of OHIM of 5 September 2012 (Case R 201/2012-2), concerning opposition proceedings between Sanofi SA and GP Pharm SA.
Operative part of the judgment
The Court:
1.Annuls the Decision of the Second Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) (OHIM) of 5 September 2012 (Case R 201/2012-2), concerning opposition proceedings between Sanofi SA and GP Pharm SA;
2.Orders OHIM to pay the costs.
(<span class="super">1</span>) OJ C 26, 26.1.2013.